Mohamed A T Ahmed1, Martin Duncan, Alison Kent. 1. Department of Neonatology, The Center for Newborn Care, The Canberra Hospital, and The ANU Medical School, Canberra, Australian Capital Territory, Australia.
Abstract
AIM: To ascertain the prevalence of significant Retinopathy of Prematurity (ROP) and ROP requiring treatment in infants born greater than 30 weeks gestation and with a birthweight greater than 1250 g, utilising the Neonatal Intensive Care Units' (NICUS) data collection from 1998 to 2002. Second, to determine whether infants delivered at more than 30 weeks gestation or with a birthweight greater than 1250 g require ROP screening. METHODS: A review of the New South Wales and Australian Capital Territory NICUS data collection from 1998 to 2002 was performed. Infants of gestational age 31-33 weeks and with a birthweight greater than 1250 g were included. A review was performed of these infants to ascertain stage of ROP, threshold disease and treatment for ROP. RESULTS: 2292 infants were greater than 30 weeks and had a birthweight greater than 1250 g. Of these 1386 (60%) were not examined or died prior to eye examination. No ROP was noted in 888 of the 904 infants examined (98%), 13 infants had stage 1 (1.4%), five infants stage 2 (0.6%) and no infant had stage 3 ROP. No infant developed stage 3 ROP, required treatment for ROP or had threshold disease. CONCLUSION: In this regional study of infants greater than 30 weeks gestation and with a birthweight greater than 1250 g, the prevalence of any ROP was low (2.0%). This study supports evidence from other studies that screening for ROP could be restricted, at least within our referral network, to infants less than 30 completed weeks and a birthweight less than 1250 g.
AIM: To ascertain the prevalence of significant Retinopathy of Prematurity (ROP) and ROP requiring treatment in infants born greater than 30 weeks gestation and with a birthweight greater than 1250 g, utilising the Neonatal Intensive Care Units' (NICUS) data collection from 1998 to 2002. Second, to determine whether infants delivered at more than 30 weeks gestation or with a birthweight greater than 1250 g require ROP screening. METHODS: A review of the New South Wales and Australian Capital Territory NICUS data collection from 1998 to 2002 was performed. Infants of gestational age 31-33 weeks and with a birthweight greater than 1250 g were included. A review was performed of these infants to ascertain stage of ROP, threshold disease and treatment for ROP. RESULTS: 2292 infants were greater than 30 weeks and had a birthweight greater than 1250 g. Of these 1386 (60%) were not examined or died prior to eye examination. No ROP was noted in 888 of the 904 infants examined (98%), 13 infants had stage 1 (1.4%), five infants stage 2 (0.6%) and no infant had stage 3 ROP. No infant developed stage 3 ROP, required treatment for ROP or had threshold disease. CONCLUSION: In this regional study of infants greater than 30 weeks gestation and with a birthweight greater than 1250 g, the prevalence of any ROP was low (2.0%). This study supports evidence from other studies that screening for ROP could be restricted, at least within our referral network, to infants less than 30 completed weeks and a birthweight less than 1250 g.